The online version of this article (doi:10.1186/1752-1947-8-304) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
JHC wrote the manuscript draft and made corrections to manuscript in light of reviewers’ comments. WHT followed up this patient as an outpatient and contributed to the discussion. CHL performed critical revision of the manuscript and supervised the study. All authors read and approved the final manuscript.
Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not been reported.
A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2 diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced her body weight by 21.2kg.
One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period.
Authors’ original file for figure 113256_2014_2922_MOESM1_ESM.pdf
Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific, Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004, 351: 2683-2693. 10.1056/NEJMoa035622. CrossRefPubMed
Vargas MA, Fernandez NC, Serrano JO: Preoperative weight loss in patients with indication of bariatric surgery: which is the best method?. Nutr Hosp. 2011, 26: 1227-1230.
Assoc AD: Standards of medical care in diabetes-2013. Diabetes Care. 2013, 36: S11-S66. CrossRef
VanGaal LF, Wauters MA, DeLeeuw IH: The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obesity. 1997, 21: S5-S9.
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A: Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011, CD006423-
Buse JB, Klonoff DC, Nielsen LL, Guan XS, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007, 29: 139-153. 10.1016/j.clinthera.2007.01.015. CrossRefPubMed
Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD: Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006, 8: 419-428. 10.1111/j.1463-1326.2006.00589.x. CrossRefPubMed
- Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report
- BioMed Central